Identifying Genes for Rectal Cancer Staging
Author Information
Author(s): Lips Esther H, van Eijk Ronald, de Graaf Eelco JR, Oosting Jan, Miranda Noel FCC, Karsten Tom, van de Velde Cornelis J, Eilers Paul HC, Tollenaar Rob AEM, van Wezel Tom, Morreau Hans
Primary Institution: Leiden University Medical Center
Hypothesis
Can integrating chromosomal aberrations and gene expression profiles help identify markers for rectal tumor staging?
Conclusion
The study identified several genes that could be used for rectal cancer characterization, including SMAD2, EFNA1, BOP1, TGIF2, and STMN3.
Supporting Evidence
- Integration of gene expression and chromosomal instability data revealed similarity between these two data types.
- Supervised analysis identified up-regulation of EFNA1 in cases with 1q gain.
- SMAD2 was the most down-regulated gene on 18q.
- BOP1 was over-expressed in cases with 8q gain.
- Immunohistochemistry for SMAD4 correlated with SMAD2 gene expression and 18q loss.
Takeaway
Researchers looked at changes in genes and chromosomes in rectal tumors to find clues about how to better stage the cancer.
Methodology
Gene expression microarray analysis was performed on 79 rectal tumors, integrating genomic data and validating results with qRT-PCR and immunohistochemistry.
Potential Biases
Potential bias due to small sample sizes in certain groups.
Limitations
The study lacked frozen material from all tumor stages for comprehensive analysis.
Participant Demographics
{"sex_ratio":"M/F 15/13","mean_age":69}
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website